ValuEngine cut shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a strong-buy rating to a buy rating in a report published on Friday morning.
Several other research firms have also recently weighed in on AMAG. BidaskClub upgraded AMAG Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, June 18th. Janney Montgomery Scott cut AMAG Pharmaceuticals from a buy rating to a neutral rating and set a $20.00 price objective on the stock. in a research report on Friday, June 15th. Cantor Fitzgerald reiterated a hold rating and set a $18.00 price objective (up previously from $17.00) on shares of AMAG Pharmaceuticals in a research report on Friday, August 3rd. B. Riley upgraded AMAG Pharmaceuticals from a neutral rating to a buy rating and increased their price objective for the stock from $23.00 to $30.00 in a research report on Friday, June 15th. Finally, Leerink Swann began coverage on AMAG Pharmaceuticals in a research report on Monday, May 21st. They set a market perform rating and a $24.65 price objective on the stock. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the stock. AMAG Pharmaceuticals presently has an average rating of Hold and an average price target of $22.85.
Shares of AMAG Pharmaceuticals stock opened at $21.65 on Friday. AMAG Pharmaceuticals has a 1 year low of $11.93 and a 1 year high of $26.10. The firm has a market cap of $801.49 million, a price-to-earnings ratio of -3.92 and a beta of 0.48. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.06 and a quick ratio of 1.95.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Thursday, August 2nd. The specialty pharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.54). AMAG Pharmaceuticals had a negative net margin of 36.87% and a negative return on equity of 2.77%. The business had revenue of $146.25 million for the quarter, compared to analyst estimates of $156.26 million. During the same period in the prior year, the business earned ($0.40) EPS. The company’s revenue for the quarter was up 12.2% compared to the same quarter last year. sell-side analysts forecast that AMAG Pharmaceuticals will post -3.43 EPS for the current fiscal year.
In other AMAG Pharmaceuticals news, CEO William K. Heiden sold 5,000 shares of the stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $25.00, for a total transaction of $125,000.00. Following the transaction, the chief executive officer now owns 328,015 shares in the company, valued at approximately $8,200,375. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.00% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of AMAG. Swiss National Bank increased its position in shares of AMAG Pharmaceuticals by 13.0% in the first quarter. Swiss National Bank now owns 63,457 shares of the specialty pharmaceutical company’s stock worth $1,279,000 after purchasing an additional 7,300 shares during the period. ClariVest Asset Management LLC bought a new position in shares of AMAG Pharmaceuticals in the first quarter worth $1,585,000. Northern Trust Corp increased its position in shares of AMAG Pharmaceuticals by 1.0% in the first quarter. Northern Trust Corp now owns 458,445 shares of the specialty pharmaceutical company’s stock worth $9,237,000 after purchasing an additional 4,468 shares during the period. Piermont Capital Management Inc. increased its position in shares of AMAG Pharmaceuticals by 664.8% in the first quarter. Piermont Capital Management Inc. now owns 100,270 shares of the specialty pharmaceutical company’s stock worth $2,020,000 after purchasing an additional 87,160 shares during the period. Finally, Employees Retirement System of Texas increased its position in shares of AMAG Pharmaceuticals by 37.5% in the first quarter. Employees Retirement System of Texas now owns 66,000 shares of the specialty pharmaceutical company’s stock worth $1,330,000 after purchasing an additional 18,000 shares during the period.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Featured Article: What Factors Can Affect Return on Equity?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.